comparision of the two methylprednisolone regimens in patient with COVID-19

Phase 1

Recruiting

Conditions: ?Acute respiratory distress syndrome of covid-19 pneumonia.
COVID-19, virus identified
U07.1

Registration Number: IRCT20130917014693N13

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 74

Inclusion Criteria

Age more than 18 years old
Severe acute respiratory injury with coronavirus infection symptoms during 10 days ago who needed for hospital admission
infection with COVID-19 wich confirmed with nasal RT_PCR test or CT-scan imaging
Mild to moderate acute respiratory distress syndrome
No more than 24 hours have passed since their admission to the study.
The patient should not be under aggressive mechanical respiration when entering the study.
Consent to participate in the study.

Exclusion Criteria

Dissatisfaction of the patient or the patient's legal companion
Pregnancy and lactation
Chronic hemodialysis
Heart failure patients
Severe vasoplegic shock
Pulmonary edema due to other causes like heart failure , cirrhosis, chronic kidney failure
Not administrating corticosteroid more than 24 hours after beginning ARDS
Severe hypoxemia
If the patient expires lower than 3 days after beginning of corticosteroids

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mortality ratio of patients with acute respiratory distress syndrome due to covid-19. Timepoint: first of admission and time of discharge. Method of measurement: Counting.

Secondary Outcome Measures

Name	Time	Method
Determine the need for respiratory support and determine changes to this support. Timepoint: every 24 hours. Method of measurement: Ventilation modality.;Determine the exact length of hospital stay until discharge. Timepoint: every 24 hours. Method of measurement: Counting number of days.;Determine the number of patients who need to receive hemoperfusion. Timepoint: Every 24 hours. Method of measurement: Count the number of patients and the frequency of hemoperfusion.;Determine the number of patients who need to receive other immunosuppressants such as tocilizumab. Timepoint: every 24 hours. Method of measurement: Counting the number of patients and the number of doses of other drugs.